Cytokinetics (CYTK) Shares Outstanding (2010 - 2026)

Cytokinetics (CYTK) has reported Shares Outstanding (Entity) for 17 consecutive years, with $123273.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 4.03% year-over-year to $123273.0; the TTM figure through Mar 2026 stood at $123273.0 (up 4.03% YoY), while the FY2025 annual figure was $120103.0, up 7.25% from the prior year.
• Shares Outstanding (Entity) grew to $123273.0 in Q1 2026 per CYTK's latest filing, from $120103.0 in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $123273.0 in Q1 2026 and bottomed at $84996.0 in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $104703.7 across 5 years, with a median of $101924.0 in 2024.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) gained 22.5% — and 2025, when it rose 1.95%.
• Cytokinetics' Shares Outstanding (Entity) stood at $89825.0 in 2022, then gained by 7.46% to $96524.0 in 2023, then increased by 16.01% to $111979.0 in 2024, then rose by 7.25% to $120103.0 in 2025, then rose by 2.64% to $123273.0 in 2026.
• Business Quant data shows CYTK's Shares Outstanding (Entity) at $123273.0 in Q1 2026, $120103.0 in Q4 2025, and $119982.0 in Q3 2025.